Michael Buckstein, MD of Mount Sinai answers commonly asked questions by his colleagues: are you overtreating the patients? What is our toxicity profile? How often do patients recur after the treatments?
______
Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort.
